Valemetostat Tosilate

N/A

Report date: 2026/05/16 20:00:17
NMEFirst In Class

Base Information

Drug NameValemetostat Tosilate
Drug Alias Nameバレメトスタットトシル酸塩Valemetostat - Daiichi SankyoValemetostat tosylateValemetostatEZHARMIA +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone-lysine N-methyltransferase EZH2 inhibitorsHistone-lysine N-methyltransferase EZH1 inhibitors
TargetsHistone-lysine N-methyltransferase EZH2Histone-lysine N-methyltransferase EZH1
Therapy Area/IndicationsSolid tumoursHepatic InsufficiencyProstatic Neoplasms, Castration-Resistant +[16] 
Global Approved IndicationsLeukemia-Lymphoma, Adult T-Cell
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2022/09/26
Country/TerritoryBelgiumCanadaUnited States +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDaiichi Sankyo (China) Holdings Co LtdDaiichi Sankyo IncNipro Pharma Corp +[6] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[12] 
Inactive IndicationsHepatic InsufficiencyCarcinoma, Non-Small-Cell LungLeukemia, Myeloid, Acute +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG